CDSCO issues alert against 62 substandard drugs; Samples from Lupin, Jackson Laboratories flagged

The Central Drugs Standard Control Organisation (CDSCO) has flagged 62 drug samples as they failed the quality test. The alert was issued by the drug regulator for November 2023.

The drug regulator’s list, as seen by Financial Express.com, reveals that 1197 drug samples were tested, out of which 1133 samples were of standard quality. 62 samples were not of standard quality, one sample was spurious and one sample was misbranded.

The list includes common drugs like Cefixime, Azithromycin and Lactic Acid Bacillus Tablets, paracetamol tablets, Albendazole Tablets, Methylcobalamin injection, Ceftriaxone injection, Methotrexate injection among other.

According to the drug regulator, dissolution, disintegration and assay are some of the reason of drug test failure. Lupin, Jackson Laboratories, E.G. Pharmaceuticals, Konis Pharmaceuticals, Biozenta Lifesciences Pvt., Aristo Pharmaceuticals, and Cotec Healthcare are some of the companies whose drug failed the quality test.

The regulator also issued a revised drug Alert for May 2022 which Omeprazole (Delayed-Release) and Domperidone (Sustained Release) Capsules, manufactured by Dr. Reddy’s Laboratories. CDSCO maintains that the assay of Omeprazole and Domperidone is the reason of failure.

“The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. Thus, the product is purported to be spurious, however, the same is subject to outcome of investigation,” it stated.

The drug combination belongs to a group of medicines called gastrointestinal agents used to treat heartburn, indigestion, epigastric pain, gastro-oesophageal reflux disease (GERD), peptic ulcers and Zollinger-Ellison syndrome.

Related Posts

  • Pharma
  • December 23, 2024
  • 43 views
Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

India’s healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According…

  • Pharma
  • December 23, 2024
  • 53 views
NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 65 new drug formulations and notified ceiling price fixation of 13 formulations. The regulatory body, under the Department of…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

India-Latin America trade and collaboration prospects discussed at Kerala University conference

India-Latin America trade and collaboration prospects discussed at Kerala University conference

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt